深圳康泰生物制品股份有限公司成立于1992年，专注于人用疫苗的研发、生产、销售，2017年2月在深交所创业板上市（股票代码 ：300601），为华南地区首个上市疫苗企业。公司总部位于深圳市，在北京、深圳两地设有5大研发产业基地，包括深圳南山区总部基地、深圳南山区新型疫苗研发生产基地、深圳光明区康泰生物园、民海生物疫苗产业基地、民海生物新型疫苗国际化产业基地，生产规模位居国内疫苗行业前列，营销及配送网络覆盖中国31个省（自治区、直辖市）。
成立30年来，康泰生物已经发展成为研发品种齐全、产品线丰富、技术优势明显的高新技术企业，具备病毒疫苗、细菌疫苗、基因工程疫苗、结合疫苗、多联多价疫苗等研发和生产能力，已上市及获得药品注册批件的产品6种，其中60微克乙肝疫苗为全球首创，无细胞百白破b型流感嗜血杆菌联合疫苗（四联疫苗）为国内独家。仅乙肝疫苗一项，康泰生物累计生产、销售了12亿多剂，帮助4亿多人免除了乙肝病毒的侵害，为国家减少公共卫生支出超过1600亿元，有着重要的经济和社会价值。公司拥有专利50余项，在研品种30余项，基本涵盖全球重点疫苗品种。
成立30年来，康泰生物已经发展成为研发品种齐全、产品线丰富、技术优势明显的高新技术企业，具备病毒疫苗、细菌疫苗、基因工程疫苗、结合疫苗、多联多价疫苗等研发和生产能力，已上市及获得药品注册批件的产品6种，其中60微克乙肝疫苗为全球首创，无细胞百白破b型流感嗜血杆菌联合疫苗（四联疫苗）为国内独家。仅乙肝疫苗一项，康泰生物累计生产、销售了12亿多剂，帮助4亿多人免除了乙肝病毒的侵害，为国家减少公共卫生支出超过1600亿元，有着重要的经济和社会价值。公司拥有专利50余项，在研品种30余项，基本涵盖全球重点疫苗品种。
Location: China, Guangdong Province, Shenzhen
Employees: 201-500
Investors 2
| Date | Name | Website |
| 13.05.2024 | Pan Lin In... | panlincap.... |
| - | 6 Dimensio... | 6dimension... |
Mentions in press and media 5
| Date | Title | Description |
| 25.03.2025 | Tariff Flexibility: A Double-Edged Sword for Markets | In the world of finance, uncertainty is like a storm cloud. It looms, casting shadows over markets and making investors uneasy. Recently, U.S. President Donald Trump hinted at “flexibility” regarding tariffs. This word, while seemingly beni... |
| 24.03.2025 | CNBC Daily Open: Tariff flexibility sounds good, but also signals uncertainty | “Flexibility” connotes openness to change. U.S. President Donald Trump expressed Friday the possibility of being flexible with tariffs, which may have helped stocks tick up, pushing the three key U.S. benchmarks into the green for the week.... |
| 21.03.2025 | AstraZeneca's Bold Leap into Beijing: A New Era for Biopharmaceutical Innovation | AstraZeneca is making waves in the biopharmaceutical ocean. The company recently announced a staggering $2.5 billion investment in Beijing. This move is not just a financial commitment; it’s a strategic pivot that could reshape the landscap... |
| 21.03.2025 | AstraZeneca to invest $2.5 billion in Beijing hub as it looks beyond Chinese tax probe | British pharmaceutical giant AstraZeneca announced on Friday that it will invest $2.5 billion in a research and development center in Beijing, China. Under the deal, AstraZeneca will enter research and development collaborations with biotec... |
| 21.03.2025 | AZN invests $2.5bn in Beijing R&D & manufacturing | AZN invests $2.5bn in Beijing R&D & manufacturing Fri, Mar 21, 2025 12:37 CET Report this content 21 March 2025 AstraZeneca to invest $2.5 billion in new global strategic R&D centre, biotech agreements and manufacturing in Beiji... |